Clinical trials
Leukemia, B-Cell trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
21 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 6 |
| Completed | 5 |
| Recruiting | 5 |
| Active, not recruiting | 3 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 4 |
| AstraZeneca | 3 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 2 |
| Acerta Pharma BV | 1 |
| Bristol-Myers Squibb | 1 |
| Celgene | 1 |
| European Institute of Oncology | 1 |
| Genzyme, a Sanofi Company | 1 |
| German CLL Study Group | 1 |
| Gruppo Italiano Studio Linfomi | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, B-Cell | 21 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 11 |
| Neoplasms | 6 |
| Lymphoma, Non-Hodgkin | 5 |
| Recurrence | 5 |
| Leukemia | 3 |
| Lymphoma, B-Cell | 3 |
| Leukemia, Lymphoid | 2 |
| Lymphoma | 2 |
| Lymphoma, Mantle-Cell | 2 |
Trials
Showing 76 to 21 of 21. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.